InnoCare

Beyond's analysis on InnoCare

• 2026-07-27 — InnoCare’s TYK2 inhibitor fadeucravacitinib (ICP-488) met the primary endpoint in its Phase III psoriasis trial, advancing the drug toward regulatory submission

Recent news mentioning InnoCare

• 2026-08-04 — InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China
• 2026-07-27 — InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study

Appears alongside

• China
• TYK2
• III

Browse the full archive →